Cardio-Tox TEEM Model for Cardiotoxicity and Arrhythmia Risk Assessment
Summary
The USPTO has published a patent application detailing the Cardio-Tox Tissue Engineered Model (TEEM). This in vitro model uses 3D human heart microtissues to assess cardiotoxicity and arrhythmia risk from test compounds, aiming to establish safe human exposure levels for environmental and pharmaceutical substances.
What changed
The United States Patent and Trademark Office (USPTO) has published patent application US20260086083A1, which describes the Cardio-Tox Tissue Engineered Model (TEEM). This invention provides an in vitro system utilizing 3D human heart microtissues to quantify dose-dependent changes in electromechanical activity, thereby enabling a comprehensive assessment of cardiotoxicity and arrhythmia risk for various compounds.
This patent application is relevant to drug manufacturers and other entities involved in chemical and toxicological screening. While this is a patent application and not a regulatory rule, it signifies innovation in methods for predicting potential adverse effects of compounds on human cardiac health. Companies in the pharmaceutical and chemical sectors may find this technology useful for developing predictive in vitro screening platforms to establish safe exposure levels for their products.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Human In Vitro Cardiotoxicity Model
Application US20260086083A1 Kind: A1 Mar 26, 2026
Inventors
Kareen L. K. Coulombe, Cassady E. Rupert, Celinda M. Kofron, Bum-Rak Choi, Taeyun Kim, Ulrike Mende
Abstract
The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.
CPC Classifications
G01N 33/5088 C12N 5/0697 G01N 1/30 G01N 21/6428 G01N 21/6456 G01N 33/5014 G06T 7/0012 G01N 2021/6439 G01N 2800/32 G06T 2207/10064 G06T 2207/30024 G06T 2207/30048
Filing Date
2025-09-24
Application No.
19338399
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.